In most respects, the widely reported patent complaint recently filed against Gilead is perfectly ordinary. It was filed in the U.S. District Court for the District of Delaware, the most common venue for patent infringement lawsuits, and alleged that a pharmaceutical company’s drug sales infringed the plaintiff’s patents on uses of the sold drug. The defendant’s response has so far been similarly unexceptional: Gilead has filed petitions for Inter Partes Review (IPR) of each asserted patent (see links below), arguing that those patents are invalid over the prior art, either as obvious or as entirely anticipated. What is remarkable about this lawsuit, however, is that the plaintiff is the government of the United States.
U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?
No Comments
Business
- IPO Top 300, 2020: Slight Decreases in Patent Grants Due to Budgets, Not COVID
- Pardon Me? Levandowski Case Highlights Need for Proactive Approach to Avoid Trade Secret Problems in Hiring
- How Patents Enable Mavericks and Challenge Incumbents
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- Trade and Commerce in West Africa and How it Influences IP Rights
Recent Posts
- Other Barks & Bites for Friday, February 26: Tillis Tells Biden to Oppose Anti-IP Efforts at WTO; China Patent Commercialization Jumps 2.5x During 13th Five-Year Plan; Federal Circuit Finds U.S. Navy Liable for Copyright Infringement
- Sarah Boone: the ‘Ironing Table’, Perfected
- How to Safeguard AI Technology: Patents versus Trade Secrets
- Dyk Splits from CAFC Panel on Application of Collateral Estoppel to Inter Partes Reexaminations
- CAFC Reverses In-Part, Vacates In-Part PTAB Finding of Patentability for Skin Cancer Detection Device